Pyk2
Proline-rich tyrosine kinase 2
Proline-rich tyrosine kinase 2 (Pyk2) is a cytoplasmic, non-receptor tyrosine kinase implicated in multiple signaling pathways. It is a negative regulator of osteogenesis and considered a viable drug target for osteoporosis treatment.
Pyk2 and focal adhesion kinase (FAK) comprise the focal adhesion kinase subfamily of non-receptor tyrosine kinases. PYK2 and FAK are large multidomain proteins containing an N-terminal FERM domain, a central catalytic domain, and a C-terminal segment containing dual proline rich (PR) subdomains and a focal adhesion targeting (FAT) region.
Pyk2, a non-receptor tyrosine kinase of the FAK family, is up-regulated in more than 60% of the tumors of hepatocellular carcinoma (HCC) patients.
All Product Categories
-
Pyk2 Related Products (22)
Related Products (22)
-
Antibodies (2)
- 1
- 2
-
Multi-kinase-IN-11
0 ImagesCat. No.: HY-18909CAS No.: 1157857-36-7
-
PF-562271 mesylate
0 ImagesCat. No.: HY-10459ACAS No.: 939791-39-6Synonyms: VS-6062 mesylatePF-562271 mesylate (VS-6062 mesylate) is an orally active, ATP-competitive, reversible FAK/Pyk2 inhibitor, with an IC50 of 1.5 nM for FAK and 13 nM for Pyk2. PF-562271 mesylate induces tumor regression, and inhibits tumor growth, invasion and metastasis. PF-562271 mesylate exerts no effect on tumor necrosis, angiogenesis or apoptosis in an orthotopic mouse model of pancreatic ductal adenocarcinoma. When combined with Sunitinib (HY-10255A), PF-562271 mesylate reduces tumor vascularization, decreases serum alpha-fetoprotein levels and improves cachexia. PF-562271 mesylate can be used in research related to prostate cancer, breast cancer, pancreatic cancer, colon cancer, glioblastoma, lung cancer, pancreatic ductal adenocarcinoma and hepatocellular carcinoma.
- 1
- 2
